BLPH
Bellerophon Therapeutics, Inc.
Set alert
52-week range unavailable
- Open
- 0.0126
- Prev close
- 0.012
- Mkt cap
- 7.91M
- Vol
- 1.56K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.012
- High
- 0.0126
- Forward P/E
- -0.45
- Beta
- 0.60
- Short ratio
- 0.39
- Inst. own
- 44.43%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 17, 2024
- 50-d avg
- 4.34
- 200-d avg
- 3.45
- 1y target
- 2.00
Key statistics
- Market cap
- 7.91M
- Enterprise value
- -8.12M
- Trailing P/E
- 0.00
- Forward P/E
- -0.45
- PEG ratio
- 0.00
- Price / sales
- 1.40
- Price / book
- 0.75
- EPS (TTM)
- -1.21
- Beta
- 0.60
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -201.56%
- Revenue (TTM)
- 5.64M
- Revenue growth
- 0.00%
- Free cash flow
- -8.17M
- Total cash
- 15.17M
- Total debt
- 8.00K
- Return on equity
- -84.92%
- Shares outstanding
- 10.45M
- Short % of float
- 5.35%
- 50-day average
- 4.34
- 200-day average
- 3.45
Analyst view
Consensus: buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Dec 17, 2024
Expected Dec 17, 2024. Consensus EPS estimate -0.40.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 17, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Sep 30, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Jul 1, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 6, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Jun 6, 2023 | Laidlaw & Co. | down | Buy | Hold |
| May 9, 2023 | Laidlaw & Co. | init | — | Buy |
| Apr 4, 2023 | HC Wainwright & Co. | reit | — | Buy |
| Nov 25, 2020 | Jefferies | init | — | Buy |
| Nov 25, 2020 | Maxim Group | init | — | Buy |
About Bellerophon Therapeutics, Inc.
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- bellerophon.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on BLPH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AMIN NASEEM M.D. | Director | Stock Award(Grant) | Jun 6, 2023 | 291,865 |
| DEKKER MARTIN | Officer | Conversion of Exercise of derivative security | Dec 8, 2022 | 17,666 |
| FERNANDES PETER | Officer | Conversion of Exercise of derivative security | Dec 8, 2022 | 22,515 |
| KIM BOBAE | Officer | Sale | May 17, 2023 | 1,723 |
| LACCONA NICHOLAS | Chief Financial Officer | Conversion of Exercise of derivative security | Dec 8, 2022 | 12,470 |
| NEW MOUNTAIN INVESTMENTS II L L C | Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 17, 2021 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Perceptive Advisors Llc | 8.90% | 930,000 | 703.54K | Mar 30, 2023 |
| Morgan Stanley | 8.63% | 901,467 | 681.96K | Mar 30, 2023 |
| Tang Capital Management, LLC | 8.55% | 893,974 | 676.29K | Mar 30, 2023 |
| Wells Fargo & Company | 1.91% | 200,066 | 151.35K | Mar 30, 2023 |
| Renaissance Technologies, LLC | 1.63% | 169,899 | 128.53K | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 1.40% | 145,810 | 110.31K | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1.36% | 142,168 | 107.55K | Dec 30, 2022 |
| Fidelity Extended Market Index Fund | 0.37% | 38,218 | 28.91K | Feb 27, 2023 |
| Fidelity Series Total Market Index Fund | 0.09% | 9,250 | 7.00K | Feb 27, 2023 |
| Fidelity Total Market Index Fund | 0.07% | 7,640 | 5.78K | Feb 27, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 4,969 | 3.76K | Feb 27, 2023 |
| Dimensional ETF Tr-Dimensional U.S. Core Equity 2 ETF | 0.04% | 4,517 | 3.42K | Jan 30, 2023 |